# Andrés J. M. Ferreri

Source: https://onco.cc/people/andres-ferreri/  
OnCo record `andres-ferreri` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the IELSG trials that made MATRix induction and consolidation the standard for primary CNS lymphoma.

## Summary

Andrés Ferreri led IELSG20, which established high-dose methotrexate plus cytarabine for primary CNS lymphoma, and IELSG32, which showed the MATRix regimen (adding rituximab and thiotepa) followed by autologous transplant or whole-brain radiotherapy produces durable remissions in most fit patients. He coordinates the International Extranodal Lymphoma Study Group and leads trials of novel agents in CNS and ocular lymphomas.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; cns-lymphoma; ielsg
- Role: Head of the Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan
- Specialisms: Primary CNS lymphoma; Extranodal lymphomas; High-dose methotrexate regimens; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Ferreri%20AJM%5BAuthor%5D%20CNS%20lymphoma

## Connected records

- cancers: [Primary CNS lymphoma](https://onco.cc/cancers/primary-cns-lymphoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- companies: [International Extranodal Lymphoma Study Group](https://onco.cc/companies/ielsg/)
- institutions: [IRCCS Ospedale San Raffaele](https://onco.cc/institutions/san-raffaele/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/andres-ferreri.json